JPWO2021113307A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021113307A5
JPWO2021113307A5 JP2022532766A JP2022532766A JPWO2021113307A5 JP WO2021113307 A5 JPWO2021113307 A5 JP WO2021113307A5 JP 2022532766 A JP2022532766 A JP 2022532766A JP 2022532766 A JP2022532766 A JP 2022532766A JP WO2021113307 A5 JPWO2021113307 A5 JP WO2021113307A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
variable region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022532766A
Other languages
English (en)
Japanese (ja)
Other versions
JP7795459B2 (ja
JP2023504271A (ja
JP2023504271A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/062815 external-priority patent/WO2021113307A2/en
Publication of JP2023504271A publication Critical patent/JP2023504271A/ja
Publication of JPWO2021113307A5 publication Critical patent/JPWO2021113307A5/ja
Publication of JP2023504271A5 publication Critical patent/JP2023504271A5/ja
Priority to JP2025260144A priority Critical patent/JP2026048871A/ja
Application granted granted Critical
Publication of JP7795459B2 publication Critical patent/JP7795459B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022532766A 2019-12-02 2020-12-02 Ｐｄ－ｌ１に対する抗体およびその使用方法 Active JP7795459B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025260144A JP2026048871A (ja) 2019-12-02 2025-12-17 Ｐｄ－ｌ１に対する抗体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962942455P 2019-12-02 2019-12-02
US62/942,455 2019-12-02
PCT/US2020/062815 WO2021113307A2 (en) 2019-12-02 2020-12-02 Antibodies against pd-l1 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025260144A Division JP2026048871A (ja) 2019-12-02 2025-12-17 Ｐｄ－ｌ１に対する抗体およびその使用方法

Publications (4)

Publication Number Publication Date
JP2023504271A JP2023504271A (ja) 2023-02-02
JPWO2021113307A5 true JPWO2021113307A5 (https=) 2024-11-15
JP2023504271A5 JP2023504271A5 (https=) 2024-11-15
JP7795459B2 JP7795459B2 (ja) 2026-01-07

Family

ID=76222467

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022532766A Active JP7795459B2 (ja) 2019-12-02 2020-12-02 Ｐｄ－ｌ１に対する抗体およびその使用方法
JP2025260144A Pending JP2026048871A (ja) 2019-12-02 2025-12-17 Ｐｄ－ｌ１に対する抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025260144A Pending JP2026048871A (ja) 2019-12-02 2025-12-17 Ｐｄ－ｌ１に対する抗体およびその使用方法

Country Status (6)

Country Link
US (1) US20230127123A1 (https=)
EP (1) EP4069294A4 (https=)
JP (2) JP7795459B2 (https=)
AU (1) AU2020396896A1 (https=)
CA (1) CA3159308A1 (https=)
WO (1) WO2021113307A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
CN121620391A (zh) * 2023-04-06 2026-03-06 金麦安博股份有限公司 用于治疗癌症的针对pd-l1和cd137的多特异性结合剂
WO2025190373A1 (en) * 2024-03-14 2025-09-18 Topmunnity Therapeutics Taiwan Limited Chimeric antigen receptor against programmed death ligand 1 (pd-l1) and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
WO2006113747A2 (en) * 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US20080280297A1 (en) * 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
US20110190157A1 (en) * 2008-08-15 2011-08-04 The Regents Of The University Of California Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia
US20120178111A1 (en) * 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
CA2886433C (en) * 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
WO2015061341A1 (en) * 2013-10-21 2015-04-30 Accuro Technologies Inc. Double barrel syringe and method to use same for placement confirmation and joint space injection
TWI716362B (zh) * 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
BR112017013176A2 (en) * 2014-12-19 2018-05-15 Dana-Farber Cancer Institute Inc. chimeric antigen receptors and methods for using them
WO2017143076A1 (en) * 2016-02-16 2017-08-24 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
KR20190003938A (ko) * 2016-02-25 2019-01-10 셀 메디카 스위처란트 아게 면역치료를 위한 변형된 세포
EP3487883B1 (en) * 2016-07-20 2023-01-04 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
CN109906232B (zh) * 2016-09-23 2023-11-07 马伦戈治疗公司 包含λ轻链和κ轻链的多特异性抗体分子
JP7269167B2 (ja) * 2016-10-14 2023-05-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド モジュラー四価二重特異性抗体プラットフォーム
AU2019235900B2 (en) * 2018-03-14 2025-12-11 Dana-Farber Cancer Institute, Inc. Engineered cells, T cell immune modulating antibodies and methods for using the same

Similar Documents

Publication Publication Date Title
US12528879B2 (en) Multi-specific binding proteins for cancer treatment
JP7809680B2 (ja) 癌処置のための多重特異性結合タンパク質
JP6702893B2 (ja) 多重特異的抗原結合タンパク質
CN118852460A (zh) 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA)
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
IL302278A (en) Combination treatment
JP2021524478A5 (https=)
EP4055045A1 (en) Multispecific antibody
JPWO2020077257A5 (https=)
JPWO2021113307A5 (https=)
US20250011422A1 (en) Siglec-6 antibodies, derivative compounds and related uses
CN120424213A (zh) 特异性结合pd-1的单克隆抗体及其医药用途
EP4448580A2 (en) Molecules that bind to cd94/nkg2a heterodimer polypeptides
EP4574844A1 (en) Multispecific antibodies having specificity for cd47 and pdl1
JPWO2023097024A5 (https=)
JPWO2023062604A5 (https=)
EA049502B1 (ru) Мультиспецифические связывающие белки для лечения рака
CN118556080A (zh) 新型肽
EA047971B1 (ru) Dll3/cd3 связывающие белки для лечения рака
JPWO2020252471A5 (https=)